Dupilumab is Effective in Young Children with Atopic Dermatitis Regardless of Type 2 Comorbidities.

Saved in:
Bibliographic Details
Title: Dupilumab is Effective in Young Children with Atopic Dermatitis Regardless of Type 2 Comorbidities.
Authors: Boguniewicz M; Department of Pediatrics, University of Colorado School of Medicine, Aurora, CO, USA.; Division of Allergy and Immunology, National Jewish Health, Denver, CO, USA., Sher LD; Peninsula Research Associates, Rolling Hills Estates, CA, USA., Paller AS; Departments of Dermatology and Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, IL, USA., Arkwright PD; Lydia Becker Institute of Immunology and Inflammation, University of Manchester, Manchester, UK., Yoshihara S; Department of Pediatrics, School of Medicine, Dokkyo Medical University, Tochigi, Japan., Smith Begolka W; National Eczema Association, Novato, CA, USA., Chen Z; Department of Pediatrics, School of Medicine, Dokkyo Medical University, Tochigi, Japan., Shah P; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA., Rodríguez Marco A; Sanofi, Madrid, Spain.
Source: Journal of asthma and allergy [J Asthma Allergy] 2026 May 19; Vol. 19, pp. 590176. Date of Electronic Publication: 2026 May 19 (Print Publication: 2026).
Publication Type: Journal Article; Comment
Journal Info: Publisher: Dove Medical Press Country of Publication: New Zealand NLM ID: 101543450 Publication Model: eCollection Cited Medium: Print ISSN: 1178-6965 (Print) Linking ISSN: 11786965 NLM ISO Abbreviation: J Asthma Allergy Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1178-6965
DOI:10.2147/JAA.S590176